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We prospectively evaluated survival after NST dUCBT for poor
risk acute leukemia or lymphoma (excluding mantle cell) in patients
without a suitably matched related donor. Eligible were patients
aged # 70 years with adequate organ function (ejection fraction .
35%; lung function . 50% predicted; total bilirubin # 2.5 mg/dl,
liver enzymes\ 5  upper limit of normal; CrCl . 40 mL/min/
1.73m2), performance score (PS) $ 60, and . 3 months after prior
autologous transplant. The preparative regimen consisted of
fludarabine 40 mg/m2 IV days –6 to -2, cyclophosphamide 50 mg/
kg IV day -6, total body irradiation 200 cGy day –1 and immunosup-
pression with a calcineurin inhibitor and mycophenolate mofetil.
G-CSF started at day 11. All patients received dUCB grafts HLA-
matched 4-6/6 (A and B at antigen level, DRB1 allele level) to the
patient and to each other. Fifty-four patients were enrolled from
16 centers; 4 of 54 patients were excluded due to progressive disease
prior to dUCBT (n 5 3) and 1 withdrew consent. The median age
was 58 yrs (range, 16-69) and weight, 79kg (range, 46-119).
Thirty-six patients had acute leukemia (64% were in CR1) and 14
patients had lymphoma. Six patients (12%) had a prior autologous
transplant. The median infused combined nucleated cell dose was
4.2  107/kg (2.3-13.6). Fifty-three percent of the units were 4/6
and 39% were 5/6 HLA-matched to the recipient; 66% of patients
received at least one 4/6 HLA-matched unit. Most patients (80%)
had PS 90-100. The median follow-up of survivors was 364 days
(range, 154-381). The 6-month probability of overall survival was
72% (95%CI, 56-83%) and progression-free survival 63% (95%
CI, 48-76%). The cumulative incidence of treatment-relatedmortal-
ity at day-180 was 20% (95%CI, 8-31%) and relapse/progression,
14% (95%CI, 4-24%). Eighteen patients died and relapse/progres-
sion was the most common cause (N5 9). The cumulative incidence
of grade II-IV acute GVHD at day 56 is 36% (95%CI, 22-50%) and
grade III-IV 10% (95%CI, 2-19%) and chronic GVHD at 180 days
was 13% (5%CI, 3-24%). The cumulative incidence of neutrophil
recovery at day 56 was 94.0% (95%CI, 87-100.0%) at a median
time of 17 days (range, 6-45). Three patients had primary and 1 sec-
ondary graft failure. These data demonstrate that NST dUCBT is
safe, reproduced results from single centers in the multicenter set-
ting, and establishes the framework for randomized trials to study al-
ternative donor NST transplantation for hematologic malignancies.
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dentical BMT and GVHD prophylaxis incorporating high dose,
post-transplantation cyclophosphamide (Cy) for patients with poor
risk leukemia or lymphoma who lacked a HLA-matched related do-
nor. The trial enrolled 55 patients from 17 centers and 52 proceeded
to transplantation. Their median age was 51 years (range, 7-70); 32
were male, and 42, Caucasian. Diagnoses included acute myeloid
(10 in CR1, 13 in CR $ 2), acute lymphocytic (3 in CR1, 3 in CR
$ 2) biphenotypic/undifferentiated leukemia in CR (n5 3) and, re-
lapsed/chemosensitive Hodgkin (n 5 8), mantle cell (n 5 3), large
cell (n 5 8), and marginal zone B cell lymphoma (n 5 1). Thirty-
nine patients had performance status $ 90%, and 12 patients had
failed prior autologous SCT. Median donor age was 43 years and
the median mismatch, 5/10 HLA alleles in the graft-versus-host di-
rection and 4/10 alleles in the host-versus-graft direction. Patients
were conditioned with Cy (14.5 mg/kg IV, day -6, -5), fludarabine
(30 mg/m2 IV, day -6 to -2), total body irradiation (200 cGy, day
-1) followed by infusion of T-cell replete bonemarrow. GVHDpro-
phylaxis consisted of Cy 50 mg/kg IV on day13 and14, mycophe-
nolate mofetil, day 15 to 135, and tacrolimus, day 15 to 1180.
Filgrastim was given from day 15 until neutrophil recovery. The
median times to . 0.5  109/L neutrophils and platelets $ 20 
109/L, were 16 and 21 days, respectively. The median donor chime-
rism in marrow/blood at day 128 was 100% (range, 70-100%), and
T cell chimerism, 100%. One patient experienced primary graft fail-
ure and none, secondary graft failure. The day 156 incidence of
acute grade II GVHD was 31% (95% CI, 18-44%) and day 1180
chronic GVHD, 11% (95% CI, 1-22%). No patient experienced
grade III-IV acute GVHD.The day1180 incidences of relapse/pro-
gression and non-relapse mortality were 19% (95% CI, 7-32%) and
5% (95% CI, 0-13%), respectively. Ten patients experienced re-
lapse/progression and there were 13 deaths: relapse/progression (n
5 8); infection (n 5 2); graft failure (n 5 1); unknown (n 5 2).
With a median follow-up of surviving patients of 294 days (range
76-650), the 6-month probabilities of overall and event-free survival
are 82% (95% CI, 65-91%) and 75% (95% CI, 59-86%), respec-
tively. These results confirm nonmyeloablative, HLA-haploidentical
BMT is feasible, associated with low toxicity and these data may be
used to plan multi-center trials to identify the optimal alternative
donor.
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Adoptive transfer of CTLs can reconstitute antiviral immunity to
EBV, CMV and Adv in allogeneic hemopoietic stem cell transplant
(HSCT) recipients. However, the time taken to prepare patient-
specific products and the lack of virus-specific T-cells in cord blood
and seronegative donors restricts application. As part of the NHLBI
Specialized Centers for Cell-Based Therapy, we are evaluating in
a multicenter setting whether infusion of ‘‘off the shelf’’ closely
HLA-matched allogeneic CTLs (CHM-CTLs) will overcome this
limitation and prove feasible, safe and effective in HSCT recipients
with infection refractory to standard therapy. Using the NHLBI
Production Assistance for Cellular Therapies program, we manufac-
tured and tested. 30 multivirus lines, which were polyclonal, com-
prising CD41 (median 10%) and CD81 (median 83%) T-cells withS151
S152 CIBMTR Best Abstract Awards for Clinical Researchspecificity for CMV, EBV and Adv (mean 1463, 101, and 227 SFC/
1x105 cells, respectively). A dose of 2x107CHM-CTL/m2 was avail-
able to subjects with persistent infection matching at least one HLA
antigen. We selected the most suitable line based on target virus
specificity through a shared allele and on overall HLA match. To
date 53 patients have been screened. A potential line was identified
for 49, of whom 29 received 1-3 infusions with lines matched at 1-
3 HLA antigens. Six subjects received CHM-CTLs for refractory
EBV-PTLD, 13 for persistent CMV, 9 for persistent Adv and one
for both CMV and Adv. There were no immediate adverse effects,
and the GVHD incidence was low, with two patients reactivating
previous acute skin or chronic GVHD, and two developing transient
skin rashes. Two patients developed thrombotic microangiopathybut had other risk factors including sirolimus treatment. Response,
defined as the overall cumulative incidence of first CR/PR in the first
26 patients by day 42 is 84.6% overall; (92.3% for CMV, 80% for
EBV and 75% for Adv). Of note, we obtained complete antiviral re-
sponses in 16 patients, and even in recipients of lines matching at
a single HLA antigen. Despite this objective antiviral activity, im-
mune monitoring studies using IFNg ELIspot assays showed little
or no rise in peripheral blood virus-reactive T cells after infusion.
Nevertheless these preliminary results show the feasibility and safety
of immunotherapy using banked CHM-CTLs. The antiviral re-
sponses we observe are encouraging and suggest that an ‘‘off-the-
shelf’’ CTL cell line may be a practical strategy for allogeneic
HSCT recipients.
